KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ionis Pharmaceuticals (IONS) Leases (2021 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Leases for 8 consecutive years, with $235.1 million as the latest value for Q1 2026.

  • For Q1 2026, Leases rose 47.59% year-over-year to $235.1 million; the TTM value through Mar 2026 reached $235.1 million, up 47.59%, while the annual FY2025 figure was $238.5 million, 47.38% up from the prior year.
  • Leases hit $235.1 million in Q1 2026 for Ionis Pharmaceuticals, down from $238.5 million in the prior quarter.
  • Across five years, Leases topped out at $242.0 million in Q3 2025 and bottomed at $159.3 million in Q1 2025.
  • Average Leases over 5 years is $184.6 million, with a median of $173.1 million recorded in 2023.
  • Year-over-year, Leases skyrocketed 910.04% in 2022 and then dropped 6.0% in 2025.
  • Ionis Pharmaceuticals' Leases stood at $181.5 million in 2022, then dropped by 5.31% to $171.9 million in 2023, then fell by 5.84% to $161.9 million in 2024, then skyrocketed by 47.38% to $238.5 million in 2025, then dropped by 1.46% to $235.1 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $235.1 million, $238.5 million, and $242.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.